Product Images Paclitaxel

This is a product description for Semisynthetic Paclitaxel Injection, USP produced by Novadoz Pharmaceuticals LLC. The product is available in two strengths, 6mg/mL and 100mg/16.7mL. The medication is intended for intravenous infusion, and caution is required, as it is a cytotoxic agent. Each mL of the injection contains 6g of paclitaxel, 527mg of Polysorbate 80, 35mg of Castor Oil, 407.5mg of Dehydrated Alcohol, USP, and 2mg of Citric Acid, USP. The product comes in a carton, and gloves should be worn when handling containers. Dosage instructions and precautions are provided, and the product should be stored between 20°C and 25°C. Contact information for Novadoz Pharmaceuticals LLC is included.*

This is a description for Paclitaxel Injection, USP which is used as a cytotoxic agent. It contains Semisynthetic Polyoxyl 35 Castor Oil and Dehychated Alcohol in a concentration of 6mg/mL and 49.7% (u/v) respectively. The drug is mainly used for intravenous infusion with unusual dosage details provided in the inserted instructions. Novadoz Pharmaceuticals LLC manufactures and distributes it, with cautionary notes regarding dilution and proper handling during usage. There is an area for coding and the manufacturing date is August 2020 with the lot number XOGKX. It should be stored between 21°t025°C in a controlled room and protected from light.*

Semisynthetic Paclitaxel Injection, USP with the concentration of 6mg/mL. Each mL contains 8mg of Paclitaxel, 527mg of Polysorbate 35, Castor Oil, NF, 407mg of Dehydrated Alcohol, USP and 2mg of Citric Acid, USP. The caution is being taken care of, as dilation before intravenous infusion is required. The medicine is a cytotoxic agent, and gloves must be worn when handling the containers. The directions and precautions for usage are available for usual dosage. The medication must be stored at a temperature between 20-25°C and should be protected from light. It is manufactured by SN Laboratories Private Limited, India, and is distributed by Novadoz Pharmaceuticals LLC. The product details are mentioned in the text, including manufacturing and expiry date.*

This is a description of a pharmaceutical product containing paclitaxel for intravenous infusion manufactured by MSN Laboratores Private Limited. Each mL of the solution contains 6 mg of pacilaxel, 527 mg of Plyoxyl, and 40.7% (v) Castor Oil NF. It is distributed by Novadoz Phamcoutials LLC and the usual dosage can be found on the insert. Dilution is required before use and it should be stored between 20° to 25°C. The product has an NDC code of 72205-063.01, a LOT number, and an expiration date of MMYYYY. The area for coding is provided, and it should be protected from light.*

This is a description of a medication called Paclitaxel Injection, USP manufactured by WSN Laboratories Private Limited. Each mL of this medication contains 6mg of paclitaxel and 527mg of Polyoxyl 35 Castor O, NF. The dosage of this medication is 30mg/5ML, available in an injection form. A caution is mentioned and a warning is given to store the medication at a cool room temperature. The text also includes some identification numbers for the medication: AR 117, NDC72205-061-01, and NOVAROZ.*

This is a description of Pacitaxel Injection, USP, a cytotoxic agent that is required to be diluted prior to intravenous infusion. Each mL of the injection contains 6 mg of Pacitaxel, 35 mg of Plyoy 36 Casor O, and 497% Dehycraed Aohol. It comes in 30 mg/5mL dosage and is usually administered as a Multiple Dose Vial. The drug must be stored between 20°C to 25°C and must be protected from light. The manufacturer of this drug is MSN Laboratories Private Limited, Telangana, India, and it is distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ, USA. The drug is packaged with LOT and EXP details over-coded to maintain privacy.*

This appears to be a statistic related to disease-free proportion in a certain population, but it is unclear what the "Humber ot sk" represents or what the units are for the percentage value provided. Further context or information is needed to provide a more precise description.*

This is a statistical report of the proportion of disease-free individuals over a period of four years. The report includes the number of participants (96,963) and events (201) as well as hazard ratio (0.83) and confidence interval (0.67-1.01). The "Number at Risk" table displays the number of individuals at risk at each year.*

This appears to be a chart or graph related to the "proportion disease free" over a certain number of years for a treatment labeled "AC+T", with a comparison to just "AC". It includes information such as the number of events (presumably related to disease), a hazard ratio, and a breakdown of the "number at risk" over the years being studied. Without more information, it is difficult to provide further context or interpretation of the data.*